Pharmaceutical group · United States
Alkermes
A group of 7 companies with 8 medicines in 4 countries.
Group structure
7 companies in 3 countries
Loading your page…
Loading your page…
Pharmaceutical group · United States
A group of 7 companies with 8 medicines in 4 countries.
7 companies in 3 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
8 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ARISTADA1064mg/3.9ml (272.82mg/ml) | 441mg/1.6ml (275.63mg/ml) | 662mg/2.4ml (275.83mg/ml) | 882mg/3.2ml (275.63mg/ml) · Suspension, extended release | Aripiprazole lauroxil | United States | Marketed | 2015 |
| ARISTADA INITIO KIT675mg/2.4ml (281.25mg/ml) · Suspension, extended release | Aripiprazole lauroxil | United States | Marketed | 2018 |
| LYBALVI10mg; 10mg base | 15mg; 10mg base | 20mg; 10mg base | 5mg; 10mg base · Tablet | Olanzapine, Samidorphan l-malate | United States | Marketed | 2021 |
| VIVITROL380mg/vial · For suspension, extended release | Naltrexone | United States | Marketed | 2006 |
| FAMPYRA 10MG Prolonged-release tablet | Fampridine | Saudi Arabia | Authorised | |
| Megestrol Alkermes | EU (EMA) | Refused | ||
| NAPRELAN375 mg · Tablet (Extended-Release) | Naproxen | Canada | Cancelled | 2007 |
| NAPRELAN500 mg · Tablet (Extended-Release) | Naproxen | Canada | Cancelled | 2007 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 4 | 4 | 0 | CompaniesAll medicines |
| Canada | 2 | 0 | 2 | CompaniesAll medicines |
| European Union (EMA) | 1 | 0 | 1 | CompaniesAll medicines |
| Saudi Arabia | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Brazil
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.
Ranked by their number of medicines.